https://ntbltc.indrap.org/questions/1-ntblcp-is-presently-involved-in-the-control-of-which-of-these-diseases/2024-09-08T16:31:03+01:00https://ntbltc.indrap.org/questions/2-the-ntblcp-has-representation-at-which-levels-of-government-in-nigeria/2024-09-08T16:33:33+01:00https://ntbltc.indrap.org/questions/strategies-of-finding-missing-tb-cases-involve/2024-09-08T16:34:35+01:00https://ntbltc.indrap.org/questions/4-whose-role-is-it-to-do-the-following-i-planning-coordination-and-policy-development-iiprovision-of-managerial-and-technical-support-iiiprocurement-and-supply-management/2024-09-08T21:25:46+01:00https://ntbltc.indrap.org/questions/5-nigeria-is-one-of-the-countries-with-high-tb-burden/2024-09-08T16:39:41+01:00https://ntbltc.indrap.org/questions/6-ntblcp-strategies-involves/2024-09-08T16:39:38+01:00https://ntbltc.indrap.org/questions/strategies-of-tb-case-finding-should-be-implemented-in/2024-09-08T16:39:41+01:00https://ntbltc.indrap.org/questions/8-an-untreated-tb-patient-can-infect-an-average-of-________-people-every-year/2024-09-08T20:29:38+01:00https://ntbltc.indrap.org/questions/9-there-is-high-prevalence-of-tb-among-children-living-with-hiv-aids/2024-09-08T20:29:39+01:00https://ntbltc.indrap.org/questions/10-end-tb-strategy-in-tb-control-is-to-last-till/2024-09-08T20:29:41+01:00https://ntbltc.indrap.org/questions/11-the-goal-of-the-ntblcp-is-to-significantly-reduce-the-burden-socio-economic-impact-and-transmission-of-tuberculosis-leprosy-and-bu-in-nigeria-in-line-with-the-sustainable-development-goals-sdgs/2024-09-08T20:29:44+01:00https://ntbltc.indrap.org/questions/12-estimated-tb-incidence-in-nigeria/2024-09-08T20:29:53+01:00https://ntbltc.indrap.org/questions/13-nigeria-is-1st-in-africa-and-6th-globally-among-30-high-tb-burden-countries/2024-09-08T20:29:54+01:00https://ntbltc.indrap.org/questions/14-tb-is-the-leading-cause-of-death-from-a-single-infectious-agent-above-hiv-aids/2024-09-08T20:29:56+01:00https://ntbltc.indrap.org/questions/15-which-of-the-following-causes-tb-in-human/2024-09-08T20:29:58+01:00https://ntbltc.indrap.org/questions/16-every-one-untreated-infectious-tb-case-infects-between-new-persons-annually/2024-09-08T20:30:00+01:00https://ntbltc.indrap.org/questions/17-integrated-patient-centred-care-and-prevention-is-one-of-the-3-pillars-of-the-end-tb-strategies/2024-09-08T20:30:05+01:00https://ntbltc.indrap.org/questions/18-the-following-are-factors-that-increases-the-likelihood-of-becoming-infected-with-tb-except/2024-09-08T20:30:07+01:00https://ntbltc.indrap.org/questions/19-tb-affect-people-mostly-within-the-age-group-25-44-years/2024-09-08T20:30:11+01:00https://ntbltc.indrap.org/questions/20-risk-of-progression-of-tb-infection-to-tb-disease-depends-on-all-of-the-following/2024-09-08T20:30:23+01:00https://ntbltc.indrap.org/questions/21-a-holistic-approach-to-ending-the-tb-epidemic-requires-a-mix-of-biomedical-public-health-and-socioeconomic-interventions-along-with-research-and-innovation/2024-09-08T20:30:24+01:00https://ntbltc.indrap.org/questions/22-persons-infected-by-m-tuberculosis-who-have-symptoms-of-tb-disease-have-what-is-known-as-latent-tb-infection-sub-clinical-infection/2024-09-08T20:30:26+01:00https://ntbltc.indrap.org/questions/23-when-a-tb-patient-talks-how-many-bacilli-is-likely-to-be-release/2024-09-08T20:30:28+01:00https://ntbltc.indrap.org/questions/24-the-most-important-source-of-tb-is-an-untreated-pulmonary-tb-ptb-patient/2024-09-08T20:30:30+01:00https://ntbltc.indrap.org/questions/25-most-public-tb-control-program-activities-are-targeted-towards-pulmonary-disease/2024-09-08T20:30:31+01:00https://ntbltc.indrap.org/questions/26-plhiv-is-not-considered-a-presumptive-tb-case-if-he-she-presents-with-cough-of-less-than-2-weeks/2024-09-08T20:30:33+01:00https://ntbltc.indrap.org/questions/27-weight-loss-persistent-fever-and-night-sweats-are-referred-to-as-general-symptoms-for/2024-09-08T20:30:34+01:00https://ntbltc.indrap.org/questions/28-the-following-are-examples-of-rapid-molecular-tests-for-diagnosing-tb-disease-except/2024-09-08T20:30:36+01:00https://ntbltc.indrap.org/questions/29-any-person-with-cough-lasting-for-2-or-more-weeks-is-a-presumptive-tb-case/2024-09-08T20:30:37+01:00https://ntbltc.indrap.org/questions/30-stool-specimen-cannot-be-use-for-xpert-mtb-rif-assay-in-tb-diagnosis-in-children/2024-09-08T20:30:40+01:00https://ntbltc.indrap.org/questions/31-all-the-following-are-tb-symptoms-in-children-except/2024-09-08T20:30:41+01:00https://ntbltc.indrap.org/questions/32-specimens-should-be-transported-using-a-cold-chain-transport-system/2024-09-08T20:30:43+01:00https://ntbltc.indrap.org/questions/33-tb-of-the-lungs-is-called-pulmonary-tuberculosis-while-that-affecting-other-organ-is-called-extra-pulmonary-tb/2024-09-08T20:30:46+01:00https://ntbltc.indrap.org/questions/34-most-public-health-tb-control-program-activities-are-targeted-towards-extra-pulmonary-tb/2024-09-08T20:30:47+01:00https://ntbltc.indrap.org/questions/35-the-most-common-symptom-of-pulmonary-tb-is-persistent-cough-lasting-two-weeks-or-more/2024-09-08T20:30:49+01:00https://ntbltc.indrap.org/questions/36-a-presumptive-tb-case-should-be-asked-to-produce-1-sputum-sample-for-genexpert-mtb-rif-test/2024-09-08T20:30:50+01:00https://ntbltc.indrap.org/questions/37-tb-screening-tool-for-identification-of-presumptive-tb-cases-include/2024-09-08T20:30:52+01:00https://ntbltc.indrap.org/questions/38-a-tb-patient-is-an-individual-who-has-been-diagnosed-to-have-tb-disease/2024-09-08T20:30:56+01:00https://ntbltc.indrap.org/questions/39-a-tb-patient-can-be-classified-broadly-based-on-the-identification-of-mycobacteria-tuberculosis-into/2024-09-08T20:30:58+01:00https://ntbltc.indrap.org/questions/40-bacteriologically-confirmed-or-clinically-diagnosed-cases-of-tb-are-also-classified-according-to/2024-09-08T20:31:02+01:00https://ntbltc.indrap.org/questions/41-a-bacteriologically-confirmed-tb-case-is-one-from-whom-a-biological-specimen-is-positive-by-any-of-the-rapid-molecular-tests/2024-09-08T20:31:04+01:00https://ntbltc.indrap.org/questions/42-a-clinically-diagnosed-tb-case-is-one-who-was-not-bacteriologically-diagnosed-but-has-been-diagnosed-with-active-tb-by-a-health-care-worker-who-has-decided-to-treat-the-patient-with-a-full-course/2024-09-08T20:31:06+01:00https://ntbltc.indrap.org/questions/43-a-new-patient-is-one-who-have-never-had-treatment-for-tb-or-who-have-taken-anti-tb-drugs-tb-medicine-for-less-than-4weeks/2024-09-08T20:31:07+01:00https://ntbltc.indrap.org/questions/44-a-relapse-patient-is-a-previously-treated-tb-patients-with-a-documented-outcome-of-cured-or-treatment-completed-at-the-end-of-their-most-recent-course-of-treatment-and-are-now-diagnosed-with-a-rec/2024-09-08T20:31:10+01:00https://ntbltc.indrap.org/questions/45-a-relapse-patient-is-a-previously-treated-tb-patient-whose-treatment-failed-in-the-most-recent-course-of-treatment/2024-09-08T20:31:12+01:00https://ntbltc.indrap.org/questions/46-case-holding-implies-that-a-patient-on-anti-tb-treatment-is-monitored-by-a-healthcare-provider-to-ensure-that-he-she-continues-and-completes-his-her-treatment-uninterrupted/2024-09-08T20:31:13+01:00https://ntbltc.indrap.org/questions/47-any-tb-patient-who-has-not-come-to-receive-his-her-treatment-for-5-consecutive-days-should-be-regarded-as-having-interrupted-treatment-and-should-therefore-be-traced/2024-09-08T20:31:15+01:00https://ntbltc.indrap.org/questions/48-for-treatment-interruptions-1-2months-do-the-following-except/2024-09-08T20:31:17+01:00https://ntbltc.indrap.org/questions/49-cured-patient-is-a-pulmonary-tb-patient-with-bacteriologically-confirmed-tb-at-the-beginning-of-treatment-who-was-smear-negative-or-culture-negative-in-the-last-month-of-treatment-and-on-at-least/2024-09-08T20:31:18+01:00https://ntbltc.indrap.org/questions/50-treatment-completed-is-when-a-tb-patient-completed-treatment-without-evidence-of-failure-but-with-no-evidence-of-sputum-smear-or-culture-results-in-the-last-month-of-treatment-or-on-at-least-one-p/2024-09-08T20:31:20+01:00https://ntbltc.indrap.org/questions/51-treatment-failed-is-a-tb-patient-whose-smear-or-culture-is-positive-at-month-4-or-later-during-treatment/2024-09-08T20:31:22+01:00https://ntbltc.indrap.org/questions/52-lost-to-follow-up-is-a-patient-who-did-not-start-treatment-or-whose-treatment-was-interrupted-for-3-consecutive-months-or-more/2024-09-08T20:31:24+01:00https://ntbltc.indrap.org/questions/53-not-evaluated-is-a-tb-patient-for-whom-no-treatment-outcome-is-assigned-this-includes-cases-transferred-out-to-another-treatment-unit-as-well-as-cases-for-whom-the-treatment-out/2024-09-08T20:31:26+01:00https://ntbltc.indrap.org/questions/54-treatment-success-is-the-difference-between-cured-and-treatment-completed/2024-09-08T20:31:28+01:00https://ntbltc.indrap.org/questions/55-importance-of-adherence-includes-the-following-except/2024-09-08T20:31:31+01:00https://ntbltc.indrap.org/questions/56-all-patients-who-interrupt-treatment-and-have-at-least-one-postive-smear-should-have-gene-xpert-done/2024-09-08T20:31:32+01:00https://ntbltc.indrap.org/questions/57-the-following-are-true-of-contact-tracing-except/2024-09-08T20:31:34+01:00https://ntbltc.indrap.org/questions/58-household-contact-is-defined-as-a-person-who-shared-the-same-enclosed-living-space-as-the-index-case-for-one-or-more-nights-or-for-frequent-or-extended-daytime-periods-during-the-3-months-before-t/2024-09-08T20:31:37+01:00https://ntbltc.indrap.org/questions/59-close-contact-of-tb-is-defined-as-a-person-who-is-in-the-household-but-do-not-share-an-enclosed-space-such-as-a-social-gathering-place-workplace-or-facility-with-the-index-case-for-extended-da/2024-09-08T20:31:38+01:00https://ntbltc.indrap.org/questions/60-the-highest-priority-contact-for-evaluation-are-except/2024-09-08T20:31:40+01:00https://ntbltc.indrap.org/questions/61-children/2024-09-08T20:31:41+01:00https://ntbltc.indrap.org/questions/62-if-symptoms-of-tb-are-present-in-children-below-5-years-preventive-treatment-should-be-given-regardless-of-whether-bcg-vaccination-has-been-given-in-the-past/2024-09-08T20:31:43+01:00https://ntbltc.indrap.org/questions/63-ensure-availability-of-inh-for-the-duration-of-at-least-3-months-before-commencing-clients-on-ipt/2024-09-08T20:31:45+01:00https://ntbltc.indrap.org/questions/64-adverse-events-associated-with-inh-as-tb-preventive-therapy-includes-the-following-except/2024-09-08T20:31:50+01:00https://ntbltc.indrap.org/questions/65-if-a-patient-missed-his-drug-refill-appointment-for/2024-09-08T20:31:51+01:00https://ntbltc.indrap.org/questions/66-if-a-patient-missed-his-drug-refill-appointment-for-8wks-the-protocol-is-to-re-start-ipt-for-6months-if-he-has-no-tb-symptoms/2024-09-08T20:31:53+01:00https://ntbltc.indrap.org/questions/67-available-treatment-options-of-tpt-ltbi-include-the-following-except/2024-09-08T20:31:55+01:00https://ntbltc.indrap.org/questions/68-contraindications-to-tpt-include-the-following-except/2024-09-08T20:31:56+01:00https://ntbltc.indrap.org/questions/69-gene-xpert-mtb-rif-system-cannot-be-use-for-follow-up/2024-09-08T20:31:58+01:00https://ntbltc.indrap.org/questions/70-the-following-are-examples-of-laboratory-tests-for-diagnosing-tb-disease-bacteriologically/2024-09-08T20:32:00+01:00https://ntbltc.indrap.org/questions/71-all-the-following-are-bacteriological-diagnosis-methods-except/2024-09-08T20:32:01+01:00https://ntbltc.indrap.org/questions/72-plhiv-is-one-of-the-priority-group-for-gene-xpert-mtb-rif-assay/2024-09-08T20:32:03+01:00https://ntbltc.indrap.org/questions/73-stool-specimen-cannot-be-use-for-xpert-mtb-rif-assay/2024-09-08T20:32:05+01:00https://ntbltc.indrap.org/questions/74-specimens-should-be-transported-using-a-cold-chain-transport-system/2024-09-08T20:32:07+01:00https://ntbltc.indrap.org/questions/75-lf-lam-is-a-urine-based-assay-that-is-recommended-for-use-in-the-diagnosis-of-tb-in-plhiv-with-advanced-disease-or-those-that-are-seriously-ill/2024-09-08T20:32:09+01:00https://ntbltc.indrap.org/questions/76-the-first-line-test-for-diagnosis-of-tuberculosis-as-adopted-by-the-ntblcp-for-both-ds-tb-and-mdr-tb-is/2024-09-08T20:32:11+01:00https://ntbltc.indrap.org/questions/77-culture-methods-remain-the-gold-standard-for-the-bacteriologic-confirmation-of-tb/2024-09-08T20:32:12+01:00https://ntbltc.indrap.org/questions/78-chest-x-ray-is-an-important-tool-in-thediagnosis-of-childhood-tb-and-tb-among-plhiv/2024-09-08T20:32:14+01:00https://ntbltc.indrap.org/questions/79-all-the-newly-diagnosed-plhiv-with-negative-screening-tests-for-tb-should-have-a-chest-x-ray/2024-09-08T20:32:16+01:00https://ntbltc.indrap.org/questions/80-for-tb-treatment-to-be-effective-it-is-crucial-that-the-following-condition-be-met-except/2024-09-08T20:32:18+01:00https://ntbltc.indrap.org/questions/81-dot-is/2024-09-08T20:32:19+01:00https://ntbltc.indrap.org/questions/82-the-following-are-the-anti-tb-drugs-used-in-nigeria-except/2024-09-08T20:32:22+01:00https://ntbltc.indrap.org/questions/83-duration-for-treatment-of-pulmonary-tb-and-extra-pulmonary-tb/2024-09-08T20:32:23+01:00https://ntbltc.indrap.org/questions/84-duration-for-treating-tb-osteomyelitis-osteo-articular-tb-and-tb-meningitis/2024-09-08T20:32:25+01:00https://ntbltc.indrap.org/questions/85-pre-treatment-weight-is-used-to-determine-the-dosage-required-at-the-start-of-treatment/2024-09-08T20:32:26+01:00https://ntbltc.indrap.org/questions/86-any-patient-on-dot-at-a-health-facility-who-did-not-come-for-his-her-drugs-for-2-days-does-not-need-to-be-traced/2024-09-08T20:32:28+01:00https://ntbltc.indrap.org/questions/87-adjunctive-steroid-therapy-may-be-useful-in-tb-pericarditis-meningitis/2024-09-08T20:32:30+01:00https://ntbltc.indrap.org/questions/88-there-is-no-need-for-strict-use-of-patient-kits-one-kit-for-one-patient/2024-09-08T20:32:32+01:00https://ntbltc.indrap.org/questions/89-re-constructive-surgery-has-a-role-in-extra-pulmonary-tb-management/2024-09-08T20:32:33+01:00https://ntbltc.indrap.org/questions/90-tb-treatment-is-divided-into-two-phases-intensive-and-continuation-phase/2024-09-08T20:32:35+01:00https://ntbltc.indrap.org/questions/91-the-following-are-aims-of-tb-treatment-except/2024-09-08T20:32:36+01:00https://ntbltc.indrap.org/questions/92-dot-allows-the-prompt-detection-and-management-of-adverse-drug-reactions-and-clinically-worsening-of-tb/2024-09-08T20:32:38+01:00https://ntbltc.indrap.org/questions/93-the-following-information-are-needed-for-assigning-tb-treatment-except/2024-09-08T20:32:41+01:00https://ntbltc.indrap.org/questions/94-diagnostic-investigations-for-tuberculosis-include-the-following/2024-09-08T20:32:42+01:00https://ntbltc.indrap.org/questions/95-the-main-components-of-tuberculosis-infection-control-are/2024-09-08T20:32:46+01:00https://ntbltc.indrap.org/questions/96-all-hiv-positive-tb-patients-should-be-started-on-cpt-to-reduce-the-occurrence-of-opportunistic-infections/2024-09-08T20:32:47+01:00https://ntbltc.indrap.org/questions/97-the-following-are-bacteriological-method-of-tb-diagnosis-except/2024-09-08T20:32:49+01:00https://ntbltc.indrap.org/questions/98-the-following-are-radiological-methods-of-tb-diagnosis-except/2024-09-08T20:32:50+01:00https://ntbltc.indrap.org/questions/99-the-following-are-correct-about-genexpert-except/2024-09-08T20:32:52+01:00https://ntbltc.indrap.org/questions/100-interpretation-of-genexpert-results-relies-on-bacterial-load/2024-09-08T20:32:56+01:00https://ntbltc.indrap.org/questions/101-all-the-statements-below-are-correct-regarding-the-burden-of-childhood-tb-in-nigeria-except-one/2024-09-08T20:32:58+01:00https://ntbltc.indrap.org/questions/102-if-specimen-is-unavailable-a-presumptive-tb-diagnosis-should-be-made-for-prompt-treatment-decision/2024-09-08T20:33:07+01:00https://ntbltc.indrap.org/questions/103-diagnosis-of-pulmonary-tb-in-children-does-not-include/2024-09-08T20:33:10+01:00https://ntbltc.indrap.org/questions/104-the-following-are-viable-strategies-in-prevention-of-tb-in-children-except/2024-09-08T20:33:12+01:00https://ntbltc.indrap.org/questions/105-a-contact-is-any-person-who-has-been-exposed-to-an-index-case/2024-09-08T20:33:14+01:00https://ntbltc.indrap.org/questions/106-all-is-correct-about-latent-tb-except-one/2024-09-08T20:33:15+01:00https://ntbltc.indrap.org/questions/107-all-the-statement-are-correct-except-one/2024-09-08T20:33:17+01:00https://ntbltc.indrap.org/questions/108-the-priority-groups-for-tb-preventive-therapy-includes/2024-09-08T20:33:20+01:00https://ntbltc.indrap.org/questions/109-priority-contacts-are-the-following-except/2024-09-08T20:33:22+01:00https://ntbltc.indrap.org/questions/110-which-of-the-following-tpt-regime-is-incorrect/2024-09-08T20:33:24+01:00https://ntbltc.indrap.org/questions/111-monitoring-and-evaluation-when-done-effectively-helps-to-improve-the-quality-of-the-tb-programme-by-ensuring/2024-09-08T20:33:26+01:00https://ntbltc.indrap.org/questions/112-the-following-are-the-importance-of-me-in-the-tb-programme/2024-09-08T20:33:29+01:00https://ntbltc.indrap.org/questions/113-the-following-are-recording-tools-of-the-tb-programme/2024-09-08T20:33:30+01:00https://ntbltc.indrap.org/questions/114-the-following-are-recording-tools-of-the-tb-programme/2024-09-08T20:33:32+01:00https://ntbltc.indrap.org/questions/115-tb-indicators-are-calculated-by-data-from-the-recording-and-reporting-tools/2024-09-08T20:33:36+01:00https://ntbltc.indrap.org/questions/116-the-term-multi-drug-resistant-tuberculosis-mdr-implies-resistance-to/2024-09-08T20:33:38+01:00https://ntbltc.indrap.org/questions/117-the-criteria-for-classification-of-tb-patients-includes/2024-09-08T20:33:41+01:00https://ntbltc.indrap.org/questions/118-some-of-the-tb-case-finding-strategy-includes/2024-09-08T20:33:46+01:00https://ntbltc.indrap.org/questions/which-statement-regarding-monitoring-of-ds-tb-treatment-is-most-correct/2024-09-08T19:35:30+01:00https://ntbltc.indrap.org/questions/monitoring-of-tb-treatment-is-done-through-these-methods-except/2024-09-08T19:37:43+01:00https://ntbltc.indrap.org/questions/121-in-monitoring-tb-treatment-using-sputum-microscopy-the-following-are-correct-except/2024-09-08T20:33:51+01:00https://ntbltc.indrap.org/questions/122-the-models-of-delivery-tb-hiv-services-at-facility-level-include/2024-09-08T20:33:55+01:00https://ntbltc.indrap.org/questions/examples-of-logistic-tools-used-in-the-ntblcp-includes/2024-09-08T19:43:24+01:00https://ntbltc.indrap.org/questions/124-the-logistic-tool-used-in-keeping-record-of-movement-and-quantity-of-a-product-in-the-facilitys-storage-area-is/2024-09-08T20:33:58+01:00https://ntbltc.indrap.org/questions/125-key-data-elements-of-ntblcp-logistic-system-includes/2024-09-08T20:33:59+01:00https://ntbltc.indrap.org/questions/126-all-is-correct-about-buruli-ulcer-except/2024-09-08T20:34:01+01:00https://ntbltc.indrap.org/questions/127-risk-factors-for-buruli-ulcer-include-all-except/2024-09-08T20:34:05+01:00https://ntbltc.indrap.org/questions/the-following-can-be-used-in-the-diagnosis-of-buruli-ulcer/2024-09-08T19:56:32+01:00https://ntbltc.indrap.org/questions/129-regarding-the-who-clinical-scoring-for-bu-which-of-the-statement-below-is-not-correct/2024-09-08T20:34:08+01:00https://ntbltc.indrap.org/questions/130-drugs-used-in-the-management-of-buruli-ulcer-include/2024-09-08T20:34:11+01:00https://ntbltc.indrap.org/questions/the-statements-below-are-correct-about-bu-control-strategies-except/2024-09-08T20:03:19+01:00https://ntbltc.indrap.org/questions/132-advocacy-can-change-the-following-in-the-tbl-programme-except/2024-09-08T20:34:15+01:00https://ntbltc.indrap.org/questions/advocacy-tools-and-techniques-include-except/2024-09-08T20:06:51+01:00https://ntbltc.indrap.org/questions/134-some-of-the-digital-tools-in-the-ntblcp-include-all-except/2024-09-08T20:34:19+01:00https://ntbltc.indrap.org/questions/135-some-of-the-new-innovations-in-the-ntblcp-include-the-following-except/2024-09-08T20:34:21+01:00https://ntbltc.indrap.org/questions/supportive-supervision-focuses-on/2024-09-08T20:10:38+01:00https://ntbltc.indrap.org/questions/137-the-pillars-of-the-end-tb-strategy-include/2024-09-08T20:34:24+01:00https://ntbltc.indrap.org/questions/cardinal-signs-of-leprosy-include/2024-09-08T20:13:19+01:00https://ntbltc.indrap.org/questions/139-all-of-the-following-statements-concerning-reactions-in-leprosy-are-correct-except/2024-09-08T20:34:26+01:00https://ntbltc.indrap.org/questions/140-key-elements-of-quality-control-include-the-following-except/2024-09-08T20:34:27+01:00https://ntbltc.indrap.org/questions/141-the-recommended-global-leprosy-target-for-grade-2-disability-among-new-leprosy-cases-is/2024-09-08T20:34:30+01:00https://ntbltc.indrap.org/questions/142-the-recommended-global-leprosy-target-for-child-proportion-among-new-cases-of-leprosy-within-the-community-is/2024-09-08T20:34:33+01:00https://ntbltc.indrap.org/questions/the-elements-of-office-management-include-the-following-except/2024-09-08T20:21:16+01:00https://ntbltc.indrap.org/questions/144-office-management-skills-include-the-following-except/2024-09-08T20:34:35+01:00https://ntbltc.indrap.org/questions/145-element-of-a-highly-functioning-team-include-all-except/2024-09-08T20:34:36+01:00https://ntbltc.indrap.org/questions/146-some-of-the-ways-to-manage-conflict-include-the-following-except/2024-09-08T20:34:38+01:00https://ntbltc.indrap.org/questions/147-cell-mediated-immunity-is-the-most-important-determinant-of-the-clinical-features-of-leprosy/2024-09-08T20:34:39+01:00https://ntbltc.indrap.org/questions/148-mdt-treatment-helps-nerves-and-organs-damaged-as-a-result-of-leprosy-to-start-functioning-again-normally/2024-09-08T20:34:40+01:00https://ntbltc.indrap.org/questions/149-reactions-are-not-a-side-effect-of-mdt/2024-09-08T20:34:42+01:00https://ntbltc.indrap.org/questions/150-leprosy-disabilities-commonly-affect-which-parts-of-the-body/2024-09-08T20:34:49+01:00https://ntbltc.indrap.org/questions/ntblcp-is-presently-involved-in-the-control-of-which-of-these-diseasescopy/2024-09-13T13:28:34+01:00https://ntbltc.indrap.org/questions/the-ntblcp-has-representation-at-which-levels-of-government-in-nigeriacopy/2024-09-13T13:28:39+01:00https://ntbltc.indrap.org/questions/strategies-of-finding-missing-tb-cases-involvecopy/2024-09-13T13:28:42+01:00https://ntbltc.indrap.org/questions/whose-role-is-it-to-do-the-following-i-planning-coordination-and-policy-development-iiprovision-of-managerial-and-technical-support-iiiprocurement-and-supply-managementcopy/2024-09-13T13:28:50+01:00https://ntbltc.indrap.org/questions/nigeria-is-one-of-the-countries-with-high-tb-burdencopy/2024-09-13T13:29:12+01:00https://ntbltc.indrap.org/questions/ntblcp-strategies-involvescopy/2024-09-13T13:29:14+01:00https://ntbltc.indrap.org/questions/strategies-of-tb-case-finding-should-be-implemented-incopy/2024-09-13T13:29:16+01:00https://ntbltc.indrap.org/questions/an-untreated-tb-patient-can-infect-an-average-of-________-people-every-yearcopy/2024-09-13T13:29:18+01:00https://ntbltc.indrap.org/questions/there-is-high-prevalence-of-tb-among-children-living-with-hiv-aidscopy/2024-09-13T13:29:19+01:00https://ntbltc.indrap.org/questions/end-tb-strategy-in-tb-control-is-to-last-tillcopy/2024-09-13T13:29:22+01:00https://ntbltc.indrap.org/questions/the-goal-of-the-ntblcp-is-to-significantly-reduce-the-burden-socio-economic-impact-and-transmission-of-tuberculosis-leprosy-and-bu-in-nigeria-in-line-with-the-sustainable-development-goals-sdgs-an/2024-09-13T13:29:24+01:00https://ntbltc.indrap.org/questions/estimated-tb-incidence-in-nigeriacopy/2024-09-13T13:29:27+01:00https://ntbltc.indrap.org/questions/nigeria-is-1st-in-africa-and-6th-globally-among-30-high-tb-burden-countriescopy/2024-09-13T13:29:29+01:00https://ntbltc.indrap.org/questions/tb-is-the-leading-cause-of-death-from-a-single-infectious-agent-above-hiv-aidscopy/2024-09-13T13:29:30+01:00https://ntbltc.indrap.org/questions/which-of-the-following-causes-tb-in-humancopy/2024-09-13T13:29:32+01:00https://ntbltc.indrap.org/questions/every-one-untreated-infectious-tb-case-infects-between-new-persons-annuallycopy/2024-09-13T13:29:34+01:00https://ntbltc.indrap.org/questions/integrated-patient-centred-care-and-prevention-is-one-of-the-3-pillars-of-the-end-tb-strategiescopy/2024-09-13T13:29:36+01:00https://ntbltc.indrap.org/questions/the-following-are-factors-that-increases-the-likelihood-of-becoming-infected-with-tb-exceptcopy/2024-09-13T13:29:37+01:00https://ntbltc.indrap.org/questions/tb-affect-people-mostly-within-the-age-group-25-44-yearscopy/2024-09-13T13:29:40+01:00https://ntbltc.indrap.org/questions/risk-of-progression-of-tb-infection-to-tb-disease-depends-on-all-of-the-following-exceptcopy/2024-09-13T13:29:42+01:00https://ntbltc.indrap.org/questions/a-holistic-approach-to-ending-the-tb-epidemic-requires-a-mix-of-biomedical-public-health-and-socioeconomic-interventions-along-with-research-and-innovation-copy/2024-09-13T13:29:43+01:00https://ntbltc.indrap.org/questions/persons-infected-by-m-tuberculosis-who-have-symptoms-of-tb-disease-have-what-is-known-as-latent-tb-infection-sub-clinical-infectioncopy/2024-09-13T13:29:45+01:00https://ntbltc.indrap.org/questions/when-a-tb-patient-talks-how-many-bacilli-is-likely-to-be-releasecopy/2024-09-13T13:29:47+01:00https://ntbltc.indrap.org/questions/the-most-important-source-of-tb-is-an-untreated-pulmonary-tb-ptb-patientcopy/2024-09-13T13:29:49+01:00https://ntbltc.indrap.org/questions/most-public-tb-control-program-activities-are-targeted-towards-pulmonary-diseasecopy/2024-09-13T13:29:50+01:00https://ntbltc.indrap.org/questions/plhiv-is-not-considered-a-presumptive-tb-case-if-he-she-presents-with-cough-of-less-than-2-weekscopy/2024-09-13T13:29:54+01:00https://ntbltc.indrap.org/questions/weight-loss-persistent-fever-and-night-sweats-are-referred-to-as-general-symptoms-forcopy/2024-09-13T13:29:56+01:00https://ntbltc.indrap.org/questions/the-following-are-examples-of-rapid-molecular-tests-for-diagnosing-tb-disease-exceptcopy/2024-09-13T13:29:59+01:00https://ntbltc.indrap.org/questions/any-person-with-cough-lasting-for-2-or-more-weeks-is-a-presumptive-tb-case-copy/2024-09-13T13:30:00+01:00https://ntbltc.indrap.org/questions/stool-specimen-cannot-be-use-for-xpert-mtb-rif-assay-in-tb-diagnosis-in-childrencopy/2024-09-13T13:30:03+01:00https://ntbltc.indrap.org/questions/all-the-following-are-tb-symptoms-in-children-exceptcopy/2024-09-13T13:30:04+01:00https://ntbltc.indrap.org/questions/specimens-should-be-transported-using-a-cold-chain-transport-systemcopy/2024-09-13T13:30:05+01:00https://ntbltc.indrap.org/questions/tb-of-the-lungs-is-called-pulmonary-tuberculosis-while-that-affecting-other-organ-is-called-extra-pulmonary-tbcopy/2024-09-13T13:30:08+01:00https://ntbltc.indrap.org/questions/most-public-health-tb-control-program-activities-are-targeted-towards-extra-pulmonary-tbcopy/2024-09-13T13:30:09+01:00https://ntbltc.indrap.org/questions/the-most-common-symptom-of-pulmonary-tb-is-persistent-cough-lasting-two-weeks-or-morecopy/2024-09-13T13:30:15+01:00https://ntbltc.indrap.org/questions/a-presumptive-tb-case-should-be-asked-to-produce-1-sputum-sample-for-genexpert-mtb-rif-testcopy/2024-09-13T13:30:16+01:00https://ntbltc.indrap.org/questions/tb-screening-tool-for-identification-of-presumptive-tb-cases-includecopy/2024-09-13T13:30:18+01:00https://ntbltc.indrap.org/questions/a-tb-patient-is-an-individual-who-has-been-diagnosed-to-have-tb-disease-copy/2024-09-13T13:30:19+01:00https://ntbltc.indrap.org/questions/a-tb-patient-can-be-classified-broadly-based-on-the-identification-of-mycobacteria-tuberculosis-intocopy/2024-09-13T13:30:21+01:00https://ntbltc.indrap.org/questions/bacteriologically-confirmed-or-clinically-diagnosed-cases-of-tb-are-also-classified-according-tocopy/2024-09-13T13:30:24+01:00https://ntbltc.indrap.org/questions/a-bacteriologically-confirmed-tb-case-is-one-from-whom-a-biological-specimen-is-positive-by-any-of-the-rapid-molecular-testscopy/2024-09-13T13:30:26+01:00https://ntbltc.indrap.org/questions/a-clinically-diagnosed-tb-case-is-one-who-was-not-bacteriologically-diagnosed-but-has-been-diagnosed-with-active-tb-by-a-health-care-worker-who-has-decided-to-treat-the-patient-with-a-full-course-of-t/2024-09-13T13:30:28+01:00https://ntbltc.indrap.org/questions/a-new-patient-is-one-who-have-never-had-treatment-for-tb-or-who-have-taken-anti-tb-drugs-tb-medicine-for-less-than-4weeks-copy/2024-09-13T13:30:30+01:00https://ntbltc.indrap.org/questions/a-relapse-patient-is-a-previously-treated-tb-patients-with-a-documented-outcome-of-cured-or-treatment-completed-at-the-end-of-their-most-recent-course-of-treatment-and-are-now-diagnosed-with-a-recurre/2024-09-13T13:30:31+01:00https://ntbltc.indrap.org/questions/a-relapse-patient-is-a-previously-treated-tb-patient-whose-treatment-failed-in-the-most-recent-course-of-treatment-copy/2024-09-13T13:30:33+01:00https://ntbltc.indrap.org/questions/case-holding-implies-that-a-patient-on-anti-tb-treatment-is-monitored-by-a-healthcare-provider-to-ensure-that-he-she-continues-and-completes-his-her-treatment-uninterrupted-copy/2024-09-13T13:30:34+01:00https://ntbltc.indrap.org/questions/any-tb-patient-who-has-not-come-to-receive-his-her-treatment-for-5-consecutive-days-should-be-regarded-as-having-interrupted-treatment-and-should-therefore-be-tracedcopy/2024-09-13T13:30:37+01:00https://ntbltc.indrap.org/questions/for-treatment-interruptions-1-2months-do-the-following-exceptcopy/2024-09-13T13:30:39+01:00https://ntbltc.indrap.org/questions/cured-patient-is-a-pulmonary-tb-patient-with-bacteriologically-confirmed-tb-at-the-beginning-of-treatment-who-was-smear-negative-or-culture-negative-in-the-last-month-of-treatment-and-on-at-least-one/2024-09-13T13:30:41+01:00https://ntbltc.indrap.org/questions/treatment-completed-is-when-a-tb-patient-completed-treatment-without-evidence-of-failure-but-with-no-evidence-of-sputum-smear-or-culture-results-in-the-last-month-of-treatment-or-on-at-least-one-previ/2024-09-13T13:30:42+01:00https://ntbltc.indrap.org/questions/treatment-failed-is-a-tb-patient-whose-smear-or-culture-is-positive-at-month-4-or-later-during-treatmentcopy/2024-09-13T13:30:44+01:00https://ntbltc.indrap.org/questions/lost-to-follow-up-is-a-patient-who-did-not-start-treatment-or-whose-treatment-was-interrupted-for-3-consecutive-months-or-morecopy/2024-09-13T13:30:46+01:00https://ntbltc.indrap.org/questions/not-evaluated-is-a-tb-patient-for-whom-no-treatment-outcome-is-assigned-this-includes-cases-transferred-out-to-another-treatment-unit-as-well-as-cases-for-whom-the-treatment-outcome/2024-09-13T13:30:47+01:00https://ntbltc.indrap.org/questions/treatment-success-is-the-difference-between-cured-and-treatment-completedcopy/2024-09-13T13:30:49+01:00https://ntbltc.indrap.org/questions/importance-of-adherence-includes-the-following-exceptcopy/2024-09-13T13:30:51+01:00https://ntbltc.indrap.org/questions/all-patients-who-interrupt-treatment-and-have-at-least-one-postive-smear-should-have-gene-xpert-done-copy/2024-09-13T13:30:53+01:00https://ntbltc.indrap.org/questions/the-following-are-true-of-contact-tracing-exceptcopy/2024-09-13T13:30:54+01:00https://ntbltc.indrap.org/questions/household-contact-is-defined-as-a-person-who-shared-the-same-enclosed-living-space-as-the-index-case-for-one-or-more-nights-or-for-frequent-or-extended-daytime-periods-during-the-3-months-before-the-s/2024-09-13T13:30:56+01:00https://ntbltc.indrap.org/questions/close-contact-of-tb-is-defined-as-a-person-who-is-in-the-household-but-do-not-share-an-enclosed-space-such-as-a-social-gathering-place-workplace-or-facility-with-the-index-case-for-extended-daytim/2024-09-13T13:30:58+01:00https://ntbltc.indrap.org/questions/the-highest-priority-contact-for-evaluation-are-exceptcopy/2024-09-13T13:30:59+01:00https://ntbltc.indrap.org/questions/children/2024-09-13T13:31:02+01:00https://ntbltc.indrap.org/questions/if-symptoms-of-tb-are-present-in-children-below-5-years-preventive-treatment-should-be-given-regardless-of-whether-bcg-vaccination-has-been-given-in-the-pastcopy/2024-09-13T13:31:03+01:00https://ntbltc.indrap.org/questions/ensure-availability-of-inh-for-the-duration-of-at-least-3-months-before-commencing-clients-on-iptcopy/2024-09-13T13:31:05+01:00https://ntbltc.indrap.org/questions/adverse-events-associated-with-inh-as-tb-preventive-therapy-includes-the-following-exceptcopy/2024-09-13T13:31:07+01:00https://ntbltc.indrap.org/questions/if-a-patient-missed-his-drug-refill-appointment-for/2024-09-13T13:31:08+01:00https://ntbltc.indrap.org/questions/if-a-patient-missed-his-drug-refill-appointment-for-8wks-the-protocol-is-to-re-start-ipt-for-6months-if-he-has-no-tb-symptoms-copy/2024-09-13T13:31:10+01:00https://ntbltc.indrap.org/questions/available-treatment-options-of-tpt-ltbi-include-the-following-exceptcopy/2024-09-13T13:31:12+01:00https://ntbltc.indrap.org/questions/contraindications-to-tpt-include-the-following-exceptcopy/2024-09-13T13:31:14+01:00https://ntbltc.indrap.org/questions/gene-xpert-mtb-rif-system-cannot-be-use-for-follow-upcopy/2024-09-13T13:31:16+01:00https://ntbltc.indrap.org/questions/the-following-are-examples-of-laboratory-tests-for-diagnosing-tb-disease-bacteriologicallycopy/2024-09-13T13:31:17+01:00https://ntbltc.indrap.org/questions/all-the-following-are-bacteriological-diagnosis-methods-exceptcopy/2024-09-13T13:31:19+01:00https://ntbltc.indrap.org/questions/plhiv-is-one-of-the-priority-group-for-gene-xpert-mtb-rif-assaycopy/2024-09-13T13:31:20+01:00https://ntbltc.indrap.org/questions/stool-specimen-cannot-be-use-for-xpert-mtb-rif-assaycopy/2024-09-13T13:31:22+01:00https://ntbltc.indrap.org/questions/specimens-should-be-transported-using-a-cold-chain-transport-systemcopy-2/2024-09-13T13:31:23+01:00https://ntbltc.indrap.org/questions/lf-lam-is-a-urine-based-assay-that-is-recommended-for-use-in-the-diagnosis-of-tb-in-plhiv-with-advanced-disease-or-those-that-are-seriously-ill-copy/2024-09-13T13:31:25+01:00https://ntbltc.indrap.org/questions/the-first-line-test-for-diagnosis-of-tuberculosis-as-adopted-by-the-ntblcp-for-both-ds-tb-and-mdr-tb-is-copy/2024-09-13T13:31:27+01:00https://ntbltc.indrap.org/questions/culture-methods-remain-the-gold-standard-for-the-bacteriologic-confirmation-of-tbcopy/2024-09-13T13:31:29+01:00https://ntbltc.indrap.org/questions/chest-x-ray-is-an-important-tool-in-thediagnosis-of-childhood-tb-and-tb-among-plhivcopy/2024-09-13T13:31:30+01:00https://ntbltc.indrap.org/questions/all-the-newly-diagnosed-plhiv-with-negative-screening-tests-for-tb-should-have-a-chest-x-raycopy/2024-09-13T13:31:32+01:00https://ntbltc.indrap.org/questions/for-tb-treatment-to-be-effective-it-is-crucial-that-the-following-condition-be-met-exceptcopy/2024-09-13T13:31:33+01:00https://ntbltc.indrap.org/questions/dot-iscopy/2024-09-13T13:31:35+01:00https://ntbltc.indrap.org/questions/the-following-are-the-anti-tb-drugs-used-in-nigeria-exceptcopy/2024-09-13T13:31:38+01:00https://ntbltc.indrap.org/questions/duration-for-treatment-of-pulmonary-tb-and-extra-pulmonary-tbcopy/2024-09-13T13:31:41+01:00https://ntbltc.indrap.org/questions/duration-for-treating-tb-osteomyelitis-osteo-articular-tb-and-tb-meningitiscopy/2024-09-13T13:31:42+01:00https://ntbltc.indrap.org/questions/pre-treatment-weight-is-used-to-determine-the-dosage-required-at-the-start-of-treatmentcopy/2024-09-13T13:31:44+01:00https://ntbltc.indrap.org/questions/any-patient-on-dot-at-a-health-facility-who-did-not-come-for-his-her-drugs-for-2-days-does-not-need-to-be-tracedcopy/2024-09-13T13:31:46+01:00https://ntbltc.indrap.org/questions/adjunctive-steroid-therapy-may-be-useful-in-tb-pericarditis-meningitiscopy/2024-09-13T13:31:49+01:00https://ntbltc.indrap.org/questions/there-is-no-need-for-strict-use-of-patient-kits-one-kit-for-one-patient-copy/2024-09-13T13:31:52+01:00https://ntbltc.indrap.org/questions/re-constructive-surgery-has-a-role-in-extra-pulmonary-tb-managementcopy/2024-09-13T13:31:54+01:00https://ntbltc.indrap.org/questions/tb-treatment-is-divided-into-two-phases-intensive-and-continuation-phasecopy/2024-09-13T13:31:56+01:00https://ntbltc.indrap.org/questions/the-following-are-aims-of-tb-treatment-except-copy/2024-09-13T13:31:58+01:00https://ntbltc.indrap.org/questions/dot-allows-the-prompt-detection-and-management-of-adverse-drug-reactions-and-clinically-worsening-of-tbcopy/2024-09-13T13:31:59+01:00https://ntbltc.indrap.org/questions/the-following-information-are-needed-for-assigning-tb-treatment-exceptcopy/2024-09-13T13:32:01+01:00https://ntbltc.indrap.org/questions/diagnostic-investigations-for-tuberculosis-include-the-followingcopy/2024-09-13T13:32:03+01:00https://ntbltc.indrap.org/questions/the-main-components-of-tuberculosis-infection-control-arecopy/2024-09-13T13:32:05+01:00https://ntbltc.indrap.org/questions/all-hiv-positive-tb-patients-should-be-started-on-cpt-to-reduce-the-occurrence-of-opportunistic-infectionscopy/2024-09-13T13:32:07+01:00https://ntbltc.indrap.org/questions/the-following-are-bacteriological-method-of-tb-diagnosis-exceptcopy/2024-09-13T13:32:09+01:00https://ntbltc.indrap.org/questions/the-following-are-radiological-methods-of-tb-diagnosis-exceptcopy/2024-09-13T13:32:11+01:00https://ntbltc.indrap.org/questions/the-following-are-correct-about-genexpert-exceptcopy/2024-09-13T13:32:12+01:00https://ntbltc.indrap.org/questions/interpretation-of-genexpert-results-relies-on-bacterial-loadcopy/2024-09-13T13:32:14+01:00https://ntbltc.indrap.org/questions/all-the-statements-below-are-correct-regarding-the-burden-of-childhood-tb-in-nigeria-except-one-copy/2024-09-13T13:32:16+01:00https://ntbltc.indrap.org/questions/if-specimen-is-unavailable-a-presumptive-tb-diagnosis-should-be-made-for-prompt-treatment-decisioncopy/2024-09-13T13:32:17+01:00https://ntbltc.indrap.org/questions/diagnosis-of-pulmonary-tb-in-children-does-not-includecopy/2024-09-13T13:32:21+01:00https://ntbltc.indrap.org/questions/the-following-are-viable-strategies-in-prevention-of-tb-in-children-exceptcopy/2024-09-13T13:32:22+01:00https://ntbltc.indrap.org/questions/a-contact-is-any-person-who-has-been-exposed-to-an-index-case-copy/2024-09-13T13:32:24+01:00https://ntbltc.indrap.org/questions/all-is-correct-about-latent-tb-except-onecopy/2024-09-13T13:32:25+01:00https://ntbltc.indrap.org/questions/all-the-statement-are-correct-except-onecopy/2024-09-13T13:32:27+01:00https://ntbltc.indrap.org/questions/the-priority-groups-for-tb-preventive-therapy-includescopy/2024-09-13T13:32:28+01:00https://ntbltc.indrap.org/questions/priority-contacts-are-the-following-exceptcopy/2024-09-13T13:32:30+01:00https://ntbltc.indrap.org/questions/which-of-the-following-tpt-regime-is-incorrectcopy/2024-09-13T13:32:33+01:00https://ntbltc.indrap.org/questions/monitoring-and-evaluation-when-done-effectively-helps-to-improve-the-quality-of-the-tb-programme-by-ensuringcopy/2024-09-13T13:32:34+01:00https://ntbltc.indrap.org/questions/the-following-are-the-importance-of-me-in-the-tb-programmecopy/2024-09-13T13:32:36+01:00https://ntbltc.indrap.org/questions/the-following-are-recording-tools-of-the-tb-programmecopy/2024-09-13T13:32:37+01:00https://ntbltc.indrap.org/questions/the-following-are-recording-tools-of-the-tb-programmecopy-2/2024-09-13T13:32:39+01:00https://ntbltc.indrap.org/questions/tb-indicators-are-calculated-by-data-from-the-recording-and-reporting-toolscopy/2024-09-13T13:32:40+01:00https://ntbltc.indrap.org/questions/the-term-multi-drug-resistant-tuberculosis-mdr-implies-resistance-tocopy/2024-09-13T13:32:42+01:00https://ntbltc.indrap.org/questions/the-criteria-for-classification-of-tb-patients-includescopy/2024-09-13T13:32:44+01:00https://ntbltc.indrap.org/questions/some-of-the-tb-case-finding-strategy-includescopy/2024-09-13T13:32:46+01:00https://ntbltc.indrap.org/questions/which-statement-regarding-monitoring-of-ds-tb-treatment-is-most-correctcopy/2024-09-13T13:32:48+01:00https://ntbltc.indrap.org/questions/monitoring-of-tb-treatment-is-done-through-these-methods-exceptcopy/2024-09-13T13:32:49+01:00https://ntbltc.indrap.org/questions/in-monitoring-tb-treatment-using-sputum-microscopy-the-following-are-correct-exceptcopy/2024-09-13T13:32:51+01:00https://ntbltc.indrap.org/questions/the-models-of-delivery-tb-hiv-services-at-facility-level-includecopy/2024-09-13T13:32:52+01:00https://ntbltc.indrap.org/questions/examples-of-logistic-tools-used-in-the-ntblcp-includescopy/2024-09-13T13:32:55+01:00https://ntbltc.indrap.org/questions/the-logistic-tool-used-in-keeping-record-of-movement-and-quantity-of-a-product-in-the-facilitys-storage-area-iscopy/2024-09-13T13:32:56+01:00https://ntbltc.indrap.org/questions/key-data-elements-of-ntblcp-logistic-system-includescopy/2024-09-13T13:32:57+01:00https://ntbltc.indrap.org/questions/all-is-correct-about-buruli-ulcer-exceptcopy/2024-09-13T13:32:59+01:00https://ntbltc.indrap.org/questions/risk-factors-for-buruli-ulcer-include-all-exceptcopy/2024-09-13T13:33:01+01:00https://ntbltc.indrap.org/questions/the-following-can-be-used-in-the-diagnosis-of-buruli-ulcercopy/2024-09-13T13:33:02+01:00https://ntbltc.indrap.org/questions/regarding-the-who-clinical-scoring-for-bu-which-of-the-statement-below-is-not-correctcopy/2024-09-13T13:33:03+01:00https://ntbltc.indrap.org/questions/drugs-used-in-the-management-of-buruli-ulcer-includecopy/2024-09-13T13:33:05+01:00https://ntbltc.indrap.org/questions/the-statements-below-are-correct-about-bu-control-strategies-exceptcopy/2024-09-13T13:33:07+01:00https://ntbltc.indrap.org/questions/advocacy-can-change-the-following-in-the-tbl-programme-exceptcopy/2024-09-13T13:33:09+01:00https://ntbltc.indrap.org/questions/advocacy-tools-and-techniques-include-exceptcopy/2024-09-13T13:33:10+01:00https://ntbltc.indrap.org/questions/some-of-the-digital-tools-in-the-ntblcp-include-all-exceptcopy/2024-09-13T13:33:12+01:00https://ntbltc.indrap.org/questions/some-of-the-new-innovations-in-the-ntblcp-include-the-following-exceptcopy/2024-09-13T13:33:13+01:00https://ntbltc.indrap.org/questions/supportive-supervision-focuses-oncopy/2024-09-13T13:33:15+01:00https://ntbltc.indrap.org/questions/the-pillars-of-the-end-tb-strategy-includecopy/2024-09-13T13:33:16+01:00https://ntbltc.indrap.org/questions/cardinal-signs-of-leprosy-includecopy/2024-09-13T13:33:18+01:00https://ntbltc.indrap.org/questions/all-of-the-following-statements-concerning-reactions-in-leprosy-are-correct-exceptcopy/2024-09-13T13:33:20+01:00https://ntbltc.indrap.org/questions/key-elements-of-quality-control-include-the-following-exceptcopy/2024-09-13T13:33:21+01:00https://ntbltc.indrap.org/questions/the-recommended-global-leprosy-target-for-grade-2-disability-among-new-leprosy-cases-iscopy/2024-09-13T13:33:23+01:00https://ntbltc.indrap.org/questions/the-recommended-global-leprosy-target-for-child-proportion-among-new-cases-of-leprosy-within-the-community-iscopy/2024-09-13T13:33:24+01:00https://ntbltc.indrap.org/questions/the-elements-of-office-management-include-the-following-exceptcopy/2024-09-13T13:33:25+01:00https://ntbltc.indrap.org/questions/office-management-skills-include-the-following-exceptcopy/2024-09-13T13:33:27+01:00https://ntbltc.indrap.org/questions/element-of-a-highly-functioning-team-include-all-exceptcopy/2024-09-13T13:33:29+01:00https://ntbltc.indrap.org/questions/some-of-the-ways-to-manage-conflict-include-the-following-exceptcopy/2024-09-13T13:33:31+01:00https://ntbltc.indrap.org/questions/cell-mediated-immunity-is-the-most-important-determinant-of-the-clinical-features-of-leprosycopy/2024-09-13T13:33:33+01:00https://ntbltc.indrap.org/questions/mdt-treatment-helps-nerves-and-organs-damaged-as-a-result-of-leprosy-to-start-functioning-again-normally-copy/2024-09-13T13:33:34+01:00https://ntbltc.indrap.org/questions/reactions-are-not-a-side-effect-of-mdtcopy/2024-09-13T13:33:36+01:00https://ntbltc.indrap.org/questions/leprosy-disabilities-commonly-affect-which-parts-of-the-bodycopy/2024-09-13T13:33:44+01:00